The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
Open accessAbstract
The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level of anti-tumor activity. In spite of this important progress, however, nearly all MM patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed MM thus represents a vital aspect of the overall care for patients with MM and a critical area of ongoing scientific and clinical research. This comprehensive manuscript from the International Myeloma Working Group provides detailed recommendations on management of relapsed disease, with sections dedicated to diagnostic evaluation, determinants of therapy, and general approach to patients with specific disease characteristics. In addition, the manuscript provides a summary of evidence from clinical trials that have significantly impacted the field, including those evaluating conventional dose therapies, as well as both autologous and allogeneic stem cell transplantation. Specific recommendations are offered for management of first and second relapse, relapsed and refractory disease, and both autologous and allogeneic transplant. Finally, perspective is provided regarding new agents and promising directions in management of relapsed MM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Those undergoing HCT typically receive a triplet regimen for 3–4 months prior to stem cell collection in order to reduce tumor cell numbers in the bone marrow.”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [34]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,512
Self-citationImproved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Self-citationTtal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 257
Liu, J., Sun, C., Tang, L. V., Wu, Y., Wang, Q., Hu, B., & Hu, Y. (2016) · Scientific Reports · doi:10.1038/srep27361 · Cited by 13
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
Weisel, K. C. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s94531 · Cited by 13
Evaluation of the safety and efficacy of daratumumab outside of clinical trials
Kobayashi, H., Tsushima, T., Terao, T., Abe, Y., Miura, D., Narita, K., Kitadate, A., Takeuchi, M., & Matsue, K. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02648-4 · Cited by 13
Cope, S. F., Toor, K., Popoff, E., Fonseca, R., Landgren, O., Mateos, M., Weisel, K. C., & Jansen, J. P. (2020) · Value in Health · doi:10.1016/j.jval.2019.11.003 · Cited by 13
Weisel, K. C., Dimopoulos, M. A., Moreau, P., Yağcı, M., Larocca, A., Kanate, A. S., Vural, F., Cascavilla, N., Basu, S., Johnson, P. R. E., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1747066 · Cited by 13
Self-citationHaertle, L., Buenache, N., Hernández, H. N. C., Šimíček, M., Šnaurová, R., Rapado, I., Martı́nez, N., López‐Muñoz, N., Sánchez‐Pina, J. M., Munawar, U., et al. (2023) · Cancers · doi:10.3390/cancers15020532 · Cited by 12
Cai, Z., Xia, Z., He, A., Dong, Y., Wang, Y., Liao, A., Song, Y., Song, J., Uhlar, C., Chastain, K. M., et al. (2024) · Cancer · doi:10.1002/cncr.35665 · Cited by 12
Carballo-Zarate, A. A., Medeiros, L. J., Fang, L., Shah, J. J., Weber, D. M., Thomas, S. K., Manasanch, E. E., Hao, S., Shen, Q., Orlowski, R. Z., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.3 · Cited by 12
Self-citationExpert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma
Offidani, M., Boccadoro, M., Raimondo, F. D., Petrucci, M. T., Tosi, P., & Cavo, M. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00507-x · Cited by 12
When and How to Treat Relapsed Multiple Myeloma
Nathwani, N., Bertamini, L., Banerjee, R. K., Gay, F., Shah, N. D., & Krishnan, A. Y. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320129 · Cited by 14
Going the distance: Are we losing patients along the multiple myeloma treatment pathway?
Terpos, E., Suzan, F., & Goldschmidt, H. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.021 · Cited by 11
Self-citationThe Prognostic Role of Lactate Dehydrogenase at First Relapse of Multiple Myeloma
Lee, H., & Jimenez-Zepeda, V. H. (2020) · Acta Haematologica · doi:10.1159/000506174 · Cited by 11
Gay, F., Günther, A., Offidani, M., Engelhardt, M. M., Salvini, M., Montefusco, V., Patriarca, F. F., Aquino, S., Pönisch, W., Spada, S., et al. (2021) · Cancer · doi:10.1002/cncr.33647 · Cited by 11
Self-citationZhang, Q., Zhu, L., Lv, W., Xu, T., Shen, C., Qian, W., Liu, P., Ying, H., He, X., Hu, C., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115098 · Cited by 10
Kumar, S. K., Leleu, X. P., Weisel, K. C., Popat, R., Suero, B., Craigie, S., Spin, P. J., Patel, L., Ramirez, A. O., Hampp, C., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.03.013 · Cited by 11
Self-citationMark, T. M., Guarneri, D., Forsberg, P. A., Rossi, A., Pearse, R. N., Perry, A., Pekle, K. A., Tegnestam, L., Greenberg, J., Shore, T. B., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.03.007 · Cited by 10
Clark, K. C., Hewett, D. R., Panagopoulos, V., Plakhova, N., Opperman, K. S., Bradey, A. L., Mrozik, K. M., Vandyke, K., Mukherjee, S., Davies, G., et al. (2020) · Cancers · doi:10.3390/cancers12082149 · Cited by 11
Lahuerta, J. J., Paiva, B., Ubieto, A. J., Sánchez-Pina, J. M., Mateos, M., Bladé, J., & Miguel, J. F. S. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003996 · Cited by 10
Self-citationWong, X. Y., Chng, W. J., Aziz, M. I. A., & Ng, K. (2021) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2022.2017285 · Cited by 10
Self-citationRichardson, P. G. G., Beksaç, M., Oriol, A., Lindsay, J., Schjesvold, F. H., Galli, M., Yağcı, M., Larocca, A., Weisel, K. C., Yu, X., et al. (2025) · European Journal Of Haematology · doi:10.1111/ejh.14365 · Cited by 9
Self-citationOcio, E. M., Montes-Gaisán, C., Bustamante, G., Garzón, S., González, E., Persona, E. P., Sirvent, M., Arguiñano, J.-M., González, Y., Ríos, R., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.10.001 · Cited by 9
Striha, A., Ashcroft, A. J., Hockaday, A., Cairns, D. A., Boardman, K., Jacques, G., Williams, C. D., Snowden, J. A., Garg, M. K., Cavenagh, J. D., et al. (2018) · Trials · doi:10.1186/s13063-018-2524-8 · Cited by 9
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma
Podar, K., & Pecherstorfer, M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1340942 · Cited by 9
Jung, J., Lee, H., Suh, Y., Eom, H., & Lee, E. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e55 · Cited by 8
Choon-Quinones, M., Hose, D., Kaló, Z., Zelei, T., Harousseau, J., Durie, B. G. M., Keown, P. A., Barnett, M., & Jakab, I. (2022) · Value in Health · doi:10.1016/j.jval.2022.04.003 · Cited by 8
Self-citationChen, Y., Fogel, L., Sun, A. Y.-E., Yang, C., Patel, R. P., Chang, W.-C., Chen, P., Jhou, H., Chen, Y., Dai, M., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14101030 · Cited by 8
Weisel, K. C., Mateos, M., Gay, F., Delforge, M., Cook, G., Szabó, Z. R., Desgraz, R., DeCosta, L., & Moreau, P. (2020) · Leukemia · doi:10.1038/s41375-020-01049-5 · Cited by 8
Self-citationTherapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis
van Nieuwenhuijzen, N., Frunt, R., May, A. M., & Minnema, M. C. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00441-3 · Cited by 8
Plasmacytoma and plasma cell myeloma affecting the jaws: A multi‐institutional collaborative study
de Souza, L. L., de CÁCERES, C. V. B. L., Vargas, P. A., Lopes, M. A., Santos‐Silva, A. R., da Silva, W. G., Ribeiro, A. C. P., Brandão, T. B., Pereira, J. C., Mesquita, R. A., et al. (2021) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.13213 · Cited by 8
Tagliafico, A. S., Rossi, F., Bignotti, B., Torri, L., Bonsignore, A., Belgioia, L., & Domineitto, A. (2021) · British Journal of Radiology · doi:10.1259/bjr.20210923 · Cited by 8
Garderet, L., Cook, G., Auner, H. W., Bruno, B., Lokhorst, H. M., Pérez‐Simón, J. A., Sahebi, F., Scheid, C., Morris, C., van Biezen, A., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1228926 · Cited by 8
Self-citationMoore, D. C., Arnall, J. R., & Plesca, D. C. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp180060 · Cited by 8
on behalf of the European Myeloma Network, Caballero‐Velázquez, T., Calderón‐Cabrera, C., López‐Corral, L., Puig, N., Márquez-Malaver, F. J., Pérez‐López, E., García-Calderón, C. B., Rosso-Fernández, C. M., Caballero, D. M., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0670-6 · Cited by 8
Self-citationREAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY
Bacher, U., Brechbühl, S., Jeker, B., & Pabst, T. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2021.012 · Cited by 6
Segura, M. R., Caballero‐Velázquez, T., Herrera, P., Patriarca, F. F., Fanin, R., Bruno, B., Einsele, H., Nahi, H., Granell, M., López‐Corral, L., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.01.026 · Cited by 8
Self-citationYue, Y., Cao, Y., Mao, X., Wang, F., Fan, P., Qian, L., Guo, S., Li, F., Guo, Y., Chen, T., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894279 · Cited by 8
Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy
Yue, Y., Cao, Y., Wang, F., Zhang, N., Qi, Z., Mao, X., Guo, S., Li, F., Guo, Y., Lin, Y., et al. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106949 · Cited by 7
Limited treatment options in refractory multiple myeloma: promising therapeutic developments
Oriol, A., Abril, L., Ibarra, G., & Senín, A. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1708721 · Cited by 7
Ailawadhi, S., Parrondo, R. D., Moustafa, M. A., LaPlant, B. R., Alegria, V. R., Chapin, D., Roy, V., Sher, T., Paulus, A., & Chanan-Khan, A. A. (2022) · Hematological Oncology · doi:10.1002/hon.3012 · Cited by 6
Zhang, B., Li, B., Xie, Y., Chang, S., Xu, Z., Hu, H., Chen, G., Zhang, T., He, J., Wu, X., et al. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023014 · Cited by 6
Chen, R., Wang, Y., Luan, C., Gao, C., Zhang, X., & Chen, B. (2017) · Journal of Cancer · doi:10.7150/jca.17999 · Cited by 6
Rekhtina, I. G., & Mendeleeva, L. P. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh2017897112-117 · Cited by 6
MDR1 polymorphisms affect the outcome of Chinese multiple myeloma patients
Xiao, Z., Yin, G., Ni, Y., Qu, X., Wu, H., Lu, H., Qian, S., Chen, L., Li, J., Qiu, H., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.142 · Cited by 6
Rago, A., Siniscalchi, A., Tordi, A., Andrizzi, C., Campagna, S., & di Toritto, T. C. (2021) · Tumori Journal · doi:10.1177/0300891621990427 · Cited by 6
Bergin, K., Yuen, F., Wallington-Beddoe, C. T., Kalff, A., Sirdesai, S., Reynolds, J., & Spencer, A. G. (2021) · British Journal of Haematology · doi:10.1111/bjh.17504 · Cited by 6
AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
Ailawadhi, S., Parrondo, R. D., Dutta, N., Han, B., Ciccio, G., Cherukuri, Y., Alegria, V. R., LaPlant, B. R., Roy, V., Sher, T., et al. (2023) · Cancers · doi:10.3390/cancers15020477 · Cited by 6
Kojovic, B., & Tariman, J. D. (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.660-664 · Cited by 6
RWD-derived response in multiple myeloma
Xu, T., Roose, J. P., Williamson, M., Sawas, A., Hong, W., Jin, H., Maignan, K., Rocci, A., Yousefi, K., Kumar, S. K., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285125 · Cited by 5
Self-citationDetection of early relapse in multiple myeloma patients
Růžičková, T., Vlachová, M., Pečínka, L., Brychtová, M., Večeřa, M., Radová, L., Ševčíková, S., Jarošová, M., Havel, J., Pour, L., et al. (2025) · Cell Division · doi:10.1186/s13008-025-00143-3 · Cited by 5
Shayanmanesh, M., Ahmadi, S. E., & Amini, A. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70790 · Cited by 4
Natural History and Prognostic Factors at First Relapse in Multiple Myeloma
Wang, C., Soekojo, C. Y., Mel, S. D., Ooi, M. G. M., Chen, Y., Goh, A. Z. K., Nagarajan, C., & Chng, W. J. (2020) · Cancers · doi:10.3390/cancers12071759 · Cited by 5
Self-citationHAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs
Huynh, M., Chang, H. Y., Lisiero, D. N., Ong, I. M., Kashyap, T., Callander, N. S., & Miyamoto, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274704 · Cited by 5
Sunami, K., Matsue, K., Suzuki, K., Takezako, N., Shinagawa, A., Sakurai, S., Tamakoshi, H., Biyukov, T. N., Peluso, T., & Richardson, P. G. G. (2020) · Cancer Science · doi:10.1111/cas.14415 · Cited by 5
Self-citationTherapy Sequencing Strategies in Multiple Myeloma: Who, What and Why?
Costello, C. L., & Mikhael, J. R. (2017) · Future Oncology · doi:10.2217/fon-2017-0493 · Cited by 5
Li, Q., Hu, L., Charwudzi, A., Zhu, W., Meng, Y., & Zhai, Z. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-021-00775-z · Cited by 4
Mittaine‐Marzac, B., de Stampa, M., Marquestaut, O., Georges, A., Ankri, J., & Aegerter, P. (2022) · Home Health Care Services Quarterly · doi:10.1080/01621424.2021.2023063 · Cited by 4
Huanglian Jiedu Decoction for treatment of multiple myeloma
An, N., Li, Y., Huang, X., Chen, C., & Xie, Y. (2020) · Medicine · doi:10.1097/md.0000000000022378 · Cited by 4
Zhong, X. Y., Diao, W., Zhao, C., & Jia, Z. (2020) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001242 · Cited by 4
Abdallah, A.-O. A., Mohyuddin, G. R., Mahmoudjafari, Z., Atrash, S., Kawsar, H. I., Sigle, M., Shune, L. O., McGuirk, J. P., & Ganguly, S. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.08.026 · Cited by 4
Zhou, Y., Xie, X., Feng, K., Cao, W., & Zhang, D. (2026) · Hematology · doi:10.1080/16078454.2026.2613505 · Cited by 3
Developments in the Field of Myeloma in the Last Decade
Saikia, T. K. (2017) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-017-0777-0 · Cited by 3
Martino, M. V., Recchia, A. G., Console, G., Gentile, M., Cimminiello, M., Gallo, G. A., Ferreri, A., Naso, V., Irrera, G., Messina, G., et al. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1387050 · Cited by 3
Lee, S.-S., & Lee, J. (2019) · Chonnam Medical Journal · doi:10.4068/cmj.2019.55.1.25 · Cited by 3
Zhang, B., Zhou, J., Lin, Q., Liu, Y., Zhang, Y., Gui, R., Song, Y., & Fang, B. (2019) · Artificial Organs · doi:10.1111/aor.13468 · Cited by 3
Mexican Consensus of Multiple Myeloma
de la Peña-Celaya, J. A., Aguilar-Luévano, J., Alcivar-Cedeño, L. M., Álvarez-Vera, J. L., Anaya-Cuéllar, I., Añorve-Hernández, É., Arana-Luna, L. L., Arteaga-Ortíz, L., Baez-Islas, P. E., Banda-García, L. I., et al. (2020) · Gaceta Médica de México · doi:10.24875/gmm.m20000392 · Cited by 4
Health-related quality of life in multiple myeloma in Kurdistan Iraq
Badi, A. A., Al-Allawi, N. S., Yassin, A., Safar, B., Abdulla, B., Shamoon, R., Amin, T., Mohamed, Z., Mohammed, A., Hussein, D., et al. (2020) · Iraqi Journal of Hematology · doi:10.4103/ijh.ijh_22_20 · Cited by 3
Ludwig, W.-D., & Schwabe, U. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_34 · Cited by 3
Alvares, D., Barrett, J., Mercier, F., Roumpanis, S., Yiu, S., Castro, F., Schulze, J., & Zhu, Y. (2025) · Statistics in Medicine · doi:10.1002/sim.10322 · Cited by 2
Paulson, R. S., Gautam, S., Medhekar, R., Mahmud, S. A., Mirsalehi, A., Ensley, L., Shelley, B., Brisbin, L., Lisi, M., Khare, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1736892 · Cited by 2
New drugs in myeloma: beware of phase I trial results, beware of cost and demand for new trials
Moreau, P. (2017) · Leukemia · doi:10.1038/leu.2017.188 · Cited by 2
Self-citationJung, S., Min, C., Lee, J. H., Mun, Y., Bang, S.-M., Yoon, D. H., Lee, H. S., Kım, K., & Lee, J. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01818-z · Cited by 2
Ocio, E. M., Montes-Gaisán, C., Bustamante, G., Garzón, S., González, E., Persona, E. P., González‐Calle, V., Sirvent, M., Arguiñano, J.-M., González, Y., et al. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.07.006 · Cited by 2
Dachs, L. R., Gaisan, C. M. M., Bustamante, G., López, S. G., García, E. G., Persona, E. P., González‐Calle, V., Sirvent, M., Pérez, J. M. A., Montes, Y. G., et al. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2240922 · Cited by 2
Raghunathachar, S. K., Krishnamurthy, K. P., Gopalaiah, L. M., Abhijith, D., Prashant, A., Parichay, S. R., & Ramesh, A. M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09892-w · Cited by 2
Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma
Sorgiovanni, I., Giudice, M. L. D., Galimberti, S., & Buda, G. (2025) · Pharmaceuticals · doi:10.3390/ph18020145 · Cited by 3
Branagan, A. R., Mo, C. C., Lei, M. M., Gustine, J. N., Yee, A. J., O’Donnell, E., Castillo, J. J., Nadeem, O., Flynn, C., Bernstein, Z. S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016513 · Cited by 2
Self-citationClinical study on ixazomib in the treatment of multiple myeloma.
He, Y., Zhang, K., Zou, L., Chen, S., Jiang, D., Hu, J., & Zhu, Y. M. (2020) · PubMed · doi:10.11817/j.issn.1672-7347.2020.200060 · Cited by 2
Offidani, M., Corvatta, L., Bringhen, S., Gentili, S., Troia, R., Maracci, L., Larocca, A., Gay, F., Leoni, P., & Boccadoro, M. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12834 · Cited by 2
The therapeutic role of natural killer cells in multiple myeloma
Mohyuddin, G. R., & Qazilbash, M. H. (2019) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.49 · Cited by 2
Gomez-Arteaga, A., Shah, G. L., Baser, R. E., Scordo, M., Ruiz, J. D., Bryant, A. J., Dahi, P. B., Ghosh, A., Lahoud, O. B., Landau, H. J., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.07.016 · Cited by 2
How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma
Morris, T. C. M., Drake, M. B., Kettle, P. J., McGuigan, T., Leahy, M., O'Dwyer, M. E., Enright, H., O’Shea, T., Popat, R., Oakervee, H. E., et al. (2021) · Clinical Hematology International · doi:10.2991/chi.k.210201.001 · Cited by 2
Richter, J. R., Anupindi, V. R., Yeaw, J., Kudaravalli, S., Zavisic, S., & Shah, D. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155221995532 · Cited by 2
Forsberg, P. A., Rossi, A., Boyer, A. S., Pearse, R. N., Pekle, K. A., Jayabalan, D. S., Lakritz, S., Flicker, K., Ribadeneyra, D., Liotta, B., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26329 · Cited by 2
A Focus on Newly Diagnosed Multiple Myeloma
Brigle, K. E., Verina, D., & Faiman, B. M. (2022) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2022.13.5.10 · Cited by 2
Zhao, W., Chen, L., Wang, L., & Wang, W. (2022) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-022-01610-5 · Cited by 2
Sandecká, V., Pour, L., Špıčka, I., Minařík, J., Radocha, J., Jelı́nek, T., Pavlíček, P., Jungová, A., Kessler, P., Wróbel, M., et al. (2022) · Neoplasma · doi:10.4149/neo_2022_220813n827 · Cited by 2
A look at treatment strategies for relapsed multiple myeloma
Cetani, G., Boccadoro, M., & Oliva, S. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1477594 · Cited by 2
Chavda, S. J., Maciocia, P. M., Mesiri, P., Counsell, N., Kothari, J., Bird, A., Mariner, C., Chew, A., Clesham, K., Moore, S. E., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15487 · Cited by 2
Forsberg, P. A., Hammes, A., Abbott, D., Sherbenou, D. W., Rossi, A., Jayabalan, D. S., Niesvizky, R., Mark, T. M., & Ely, S. A. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1551537 · Cited by 2
Gassiot, S., González, Y., Morgades, M., Motlló, C., Clapés, V., Maluquer, C., Ibarra, G., Abril, L., Ribera, J., & Oriol, A. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.05.020 · Cited by 2
Monoclonal antibody utilization characteristics in patients with multiple myeloma
Ailawadhi, S., Sher, T., Azzouqa, A., Meghji, Z., Jain, T., Jani, P., Ahmed, S., Diehl, N. N., Roy, V., Shah, V. S., et al. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000810 · Cited by 2
Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
Семочкин, С. В. (2020) · Oncohematology · doi:10.17650/1818-8346-2020-15-2-29-41 · Cited by 2
Liang, X., Guo, X., Jin, H., Shen, L., Ding, L., Guan, X., Kou, Y., Wu, Y., & Guo, H. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12557 · Cited by 1
Wang, Y., Dai, Z., Xiao, S., Zeng, F., & Lu, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-02036-x · Cited by 1
Jenner, M. W., Boyd, K. D., Choudhuri, S., Parrish, C., Garg, M. K., Stern, S., & the British Society of Haematology and UK Myeloma Society (2025) · British Journal of Haematology · doi:10.1111/bjh.70149 · Cited by 2
Optimising Treatment in Relapsed, Refractory Multiple Myeloma
Minnema, M. C., & Gavriatopoulou, M. (2018) · European Oncology & Haematology · doi:10.17925/eoh.2018.14.2.96 · Cited by 1
Deng, S., Xu, Y., Sui, W. W., An, G. C., Mao, X. H., Li, Z. J., Zou, D. H., & Qiu, L. (2017) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2017.06.005 · Cited by 1
Ludwig, W.-D., & Schwabe, U. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_37 · Cited by 1
Ludwig, W.-D., & Schwabe, U. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_37 · Cited by 1
Kotb, R. R., Hart, C., & Goubran, H. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-10131-1_11 · Cited by 1
Metadata
- Authors
- Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., Jurczyszyn, A., Ludwig, H., Mellqvist, U.-H., Chng, W.-J., Pilarski, L., Einsele, H., Hou, J., Turesson, I., Zamagni, E., Chim, C. S., Mazumder, A., Westin, J., Lu, J., Reiman, T., Kristinsson, S., Joshua, D., Roussel, M., O'Gorman, P., Terpos, E., McCarthy, P., Dimopoulos, M., Moreau, P., Orlowski, R. Z., Miguel, J. S., Anderson, K. C., Palumbo, A., Kumar, S., Rajkumar, V, Durie, B., & Richardson, P. G.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Hôpital Saint-Antoine (FR)
- University of California, San Francisco (US)
- Karolinska University Hospital (SE)
- Centre Hospitalier Universitaire de Liège (BE)
- Istanbul Memorial Hospital (TR)
- University of North Carolina at Chapel Hill (US)
- Centre Hospitalier Universitaire de Lille (FR)
- Aalborg University Hospital (DK)
- King's College Hospital (GB)
- Jagiellonian University (PL)
- Wilhelminen Hospital (AT)
- Sahlgrenska University Hospital (SE)
- National University of Singapore (SG)
- University of Alberta (CA)
- Universitätsklinikum Würzburg (DE)
- Second Military Medical University (CN)
- Skåne University Hospital (SE)
- University of Bologna (IT)
- Queen Mary Hospital (CN)
- NYU Langone Health (US)
- Peking University People's Hospital (CN)
- Dalhousie University (CA)
- Royal Prince Alfred Hospital (AU)
- Hôpital Purpan (FR)
- National and Kapodistrian University of Athens (GR)
- Roswell Park Comprehensive Cancer Center (US)
- Nantes Université (FR)
- The University of Texas MD Anderson Cancer Center (US)
- University of Turin (IT)
- Mayo Clinic (US)
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Richardson, P G
- ORCID
- Laubach, J
- Garderet, L
- Caers, J
- Sezer, O
- Voorhees, P
- Leleu, X
- Johnsen, H E
- Streetly, M
- Jurczyszyn, A
- Ludwig, H
- Einsele, H
- Hou, J
- Turesson, I
- Zamagni, E
- Chim, C S
- Mazumder, A
- Reiman, T
- Kristinsson, S
- Roussel, M
- Terpos, E
- McCarthy, P
- Dimopoulos, M
- Moreau, P
- Orlowski, R Z
- Anderson, K C
- Palumbo, A
- Kumar, S
- Durie, B
- Richardson, P G
- Venue
- Leukemia
- Published
- 2015-12-29
- Volume
- 30
- Issue
- 5
- Pages
- 1005-1017
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2216303864
- Cited by
- 258
- References
- 133
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 10 · 2023: 33 · 2022: 24 · 2021: 25 · 2020: 35 · 2019: 29 · 2018: 32 · 2017: 38 · 2016: 10
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- relapsed multiple myeloma, relapsed/refractory multiple myeloma, second relapse, autologous stem cell transplantation, allogeneic stem cell transplantation, conventional-dose chemotherapy, diagnostic assessment, treatment selection
- MeSH terms
- Antineoplastic Agents, Humans, Multiple Myeloma, Recurrence, Salvage Therapy, Practice Guidelines as Topic, Hematopoietic Stem Cell Transplantation, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
